Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > BUSINESS
BUSINESS
- Nichi-Iko Files Remicade Biosimilar in Japan
October 1, 2015
- Sato, POLA to Jointly Market Clenafin Competitor Drug
October 1, 2015
- Eisai Ups April-Sept. Profit Forecasts on Lower Sales
October 1, 2015
- Asahi Kasei Pharma Seek Japan Approval of Once-Yearly Osteoporosis Drug
October 1, 2015
- Astellas Licenses Analgesic Ion Channel Blocker from US Chromocell
October 1, 2015
- Fujifilm to Establish Cellular Dynamics Japan for iPS Biz
September 30, 2015
- CMIC Holdings CEO to Double as OrphanPacific Chairman
September 30, 2015
- Halaven Now under FDA’s Priority Review for Soft Tissue Sarcoma: Eisai
September 30, 2015
- Janssen Seeks Pediatric Use for Ultiva in Japan
September 30, 2015
- Amgen Astellas Building Sales Force before PCSK9 Approval
September 29, 2015
- GSK to Compensate for Add’l Patient Burdens Tied to Hep B Drug Shortage
September 29, 2015
- Takeda Files Nesina-Metformin Combo Drug in Japan
September 29, 2015
- Celgene Launches Japan PI for Pleiotropic Pathway Modifier
September 29, 2015
- Chugai to Create New Post to Gear Up for HTA Introduction
September 28, 2015
- Maruho Files NDA for Japan’s First Infantile Hemangioma Treatment
September 28, 2015
- MEDINET Partners with Univ. of Tokyo in Joint Research for iPS Immuno-Cell Therapy
September 28, 2015
- Nihon Generic to Build New Factory with 10 Billion-Tablet Capacity
September 25, 2015
- MTPC, MedImmune Hook Up on Antibody Drug Conjugates
September 25, 2015
- NICE Recommends New Lixiana Indication for Health Coverage: Daiichi Sankyo
September 25, 2015
- Taiho Gets FDA Nod for Lonsurf, Its First Approval in US
September 25, 2015
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…